Results 41 to 50 of about 1,753 (162)

Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis

, 2023
BACKGROUND: Lebrikizumab, a high-affinity IgG4 monoclonal antibody targeting interleukin-13, prevents the formation of the interleukin-4Rα-interleukin-13Rα1 heterodimer receptor signaling complex.
Silverberg, Jonathan I, Guttman-Yassky, Emma, Blauvelt, Andrew, Gontijo Lima, Renata, Chu, Chia-Yu, Thaçi, Diamant, Irvine, Alan D, Seneschal, Julien, Simpson, Eric L, Pillai, Sreekumar G, Liu, Zhuqing, Stein Gold, Linda F   +11 more
core   +4 more sources

When Treatment Meets Natural History: Understanding Early Dermatitis‐Related Adverse Events in Systemic Atopic Dermatitis Trials

JEADV Clinical Practice, EarlyView.
ABSTRACT Biologics and Janus kinase (JAK) inhibitors have transformed the management of atopic dermatitis (AD), yet some patients experience early worsening of disease activity during treatment initiation. In clinical trials, these events are typically recorded as treatment‐emergent adverse events (TEAEs), most commonly coded as “atopic dermatitis”. We
Diego Ruiz Dasilva, Alondra Soto‐Gonzalez, Haya Alkiswani, Graham H. Litchman, Harrison Nguyen, Gil Yosipovitch, Firas George Hougeir, Matthew Zirwas, David Cotter, Brad Glick, E. James Song, Christopher G. Bunick, Neal Bhatia, Adam Friedman, Leon Kircik, Mona Shahriari, Peter Lio, James Del Rosso   +17 more
wiley   +1 more source

Effect of Dupilumab on Airway Inflammation in Patients With Persistent Asthma

Allergy, EarlyView.
EXPEDITION (NCT02573233) assessed the effects of dupilumab on airway inflammation in patients with persistent asthma using bronchoscopy and gene expression analysis. Dupilumab showed no appreciable effect on inflammatory cell types in biopsies or BALF samples.
Michael E. Wechsler, Sally E. Wenzel, Steve D. Groshong, Mario Castro, Ian D. Pavord, Klaus F. Rabe, Elizabeth Laws, Alexandre Jagerschmidt, Kaitlyn Gayvert, Sivan Harel, Jennifer D. Hamilton, Nikhil Amin, Lu Zhang, Heming Xing, Anissa Elfakir, Bema Coulibaly, Souâd Naimi, Sara Hamon, Paul J. Rowe, Frank Nestle, Danen M. Cunoosamy, Emanuele de Rinaldis, Leda P. Mannent   +22 more
wiley   +1 more source

Differential Roles for IL‐4Rα and IL‐13Rα1 in Immune Cell Infiltration and Epithelial Remodeling in Experimental Eosinophilic Gastritis

Allergy, EarlyView.
This study described the development of an experimental model for eosinophilic gastritis (EoG). Experimental EoG recapitulates histopathological features of human disease. including foveolar elongation, fibrosis, eosinophilia, mastocytosis and shared transcriptional programs.
Anish Dsilva, Shraddha Sharma, Shireen Barakey, Ariel Wagner, Alice Keisar, Tali Bar‐on, Michal Itan, Ariel Munitz   +7 more
wiley   +1 more source

Targeting Interleukin 13 for the Treatment of Atopic Dermatitis

Pharmaceutics, 2023
Atopic dermatitis (AD) is a common chronic inflammatory skin condition that has a significant impact on a patient’s quality of life and requires ongoing management.
Yuliya Lytvyn, Melinda Gooderham
doaj   +1 more source

Serum‐Proteomic Profiling Reveals Distinct Atopic Dermatitis Severity‐Linked Signatures

Allergy, EarlyView.
This study aimed to identify a set of serum biomarkers that robustly distinguish prespecified severe from mild atopic dermatitis groups. Serum proteomic profiling distinguishes severe from mild atopic dermatitis, revealing an epithelial enriched severity footprint linked to LDH‐associated tissue injury and Th2/Th22 inflammation.
Jag S. Lally, Takeshi Yoshida, Shan Gao, Xueya Cai, Donald Y. M. Leung, Lisa A. Beck, Anna De Benedetto   +6 more
wiley   +1 more source

Lebrikizumab Combined with Topical Corticosteroids Improves Patient-reported Outcomes in Japanese Patients with Moderate-to-severe Atopic Dermatitis

Acta Dermato-Venereologica
Lebrikizumab has previously demonstrated efficacy in Phase 3 trials: ADvocate1 and ADvocate2 (as monotherapy), ADhere, and ADhere-J (in combination with topical corticosteroids).
Akio Tanaka, Ken Igawa, Hidetoshi Takahashi, Ryosuke Shimizu, Yoko Kataoka, Hitoe Torisu-Itakura, Yoji Morisaki, Sonia Montmayeur, Norito Katoh   +8 more
doaj   +1 more source

Anti-inflammatory and biologic drugs for atopic dermatitis: a therapeutic approach in children and adolescents

Frontiers in Medicine, 2023
Atopic dermatitis (AD) is a chronic inflammatory disease with a heterogeneous pathogenesis correlated with dysregulation of the immune system and a prevalence of the T2-mediated immune pathway.
Carlo Caffarelli, Arianna Giannetti, Giuliana Giannì, Giampaolo Ricci   +3 more
doaj   +1 more source

Effect of Abrocitinib on the Skin Microbiome in Patients With Moderate‐to‐Severe Atopic Dermatitis

Allergy, EarlyView.
Atopic dermatitis (AD) is characterized by microbial dysbiosis. This study aimed to evaluate the effects of abrocitinib, a JAK1‐selective inhibitor, on the skin microbiome and its potential associations with clinical outcomes in patients with AD. Abrocitinib treatment was associated with increased skin microbial diversity and decreased Staphylococcus ...
Madeline Kim, Ester Del Duca, Joel Correa Da Rosa, Juliana Pulsinelli, Yeriel Estrada, Dan Xu, Gary Chan, Allshine Chen, Erman Güler, Karen Page, Emma Guttman‐Yassky   +10 more
wiley   +1 more source

Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical Trials [PDF]

, 2023
BACKGROUND: Lebrikizumab is a monoclonal antibody that binds with high affinity to interleukin (IL)-13, thereby blocking the downstream effects of IL-13 with high potency.
de Bruin-Weller, Marjolein, Zhao, Fangyi, Thyssen, Jacob P, Moore, Angela, Thaçi, Diamant, Natalie, Chitra R, Elmaraghy, Hany, Stein Gold, Linda F, Gooderham, Melinda, Meskimen, Eric, Laquer, Vivian, Gallo, Gaia, Montmayeur, Sonia, Jimenez, Gemma   +13 more
core   +2 more sources